Anti-IL-11 hybridoma antibody and application thereof in inhibition of fibrosis
By preparing and designing high-affinity anti-IL-11 human mouse chimeric antibody, the problem of insufficient affinity of existing IL-11 antibodies is solved, effective inhibition of fibrosis-related genes and proteins is achieved, and the fibrosis area is significantly reduced. Broad medical prospects.
Patent Information
- Application Number
- CN202411012202.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-07-26
AI Technical Summary
The antigen affinity obtained by humanization of existing IL-11 antibodies is relatively weak and it is difficult to effectively inhibit fibrosis.
Hybridoma cells that produce murine monoclonal antibodies were prepared using recombinant human IL11/recombinant monkey IL11 protein as antigen, and hybridoma cell lines specifically bound to human, mouse and monkey IL11 were obtained. The 5'RACE technology of TAKARA was obtained. Variable region sequence, humanized heavy and light chain sequences are designed, anti-IL-11 human mouse chimeric antibody is constructed, and its affinity is enhanced, and humanized design is carried out through 3D modeling methods to improve the affinity and blockade of the antibody. active.
The obtained anti-IL-11 hybridoma antibody has extremely strong affinity and can effectively inhibit the expression of fibrosis-related genes and proteins induced by TGFβ, significantly reduce the fibrosis area, and is suitable for clinical experiments.
Smart Images

Figure CN118994388A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of drug detection, and specifically relates to an anti-IL-11 hybridoma antibody and an application thereof in inhibiting fibrosis. Background Art
[0002] Interleukin-11 is a stromal cell-derived cytokine that belongs to the IL-6 superfamily. It is secreted by various cell types, including osteoblasts, synoviocytes, fibroblasts, chondrocytes, and trophoblasts. It then binds to IL-11Ralpha and GP130 receptors and activates the downstream JAK / STAT signaling pathway.
[0003] More and more studies have found that IL-11 plays an extremely important role in the fields of cell protection, anti-inflammation and anti-fibrosis in organs such as the lungs. IL-11 is secreted by polarized cells or fibroblasts after injury and has autocrine and paracrine effects. In polarized cells, IL-11 causes cell dysfunction, initiates apoptotic cell death, and blocks regeneration. In stromal cells, IL-11 triggers extracellular matrix production, invasion and migration of myofibroblasts. IL-11-activated fibroblasts and myofibroblasts secrete cytokines and chemokines, which have strong pro-inflammatory effects. Inhibition of IL-11 can protect the parenchyma, resist fibrosis, and reduce matrix-driven inflammation. In tissues with regenerative capacity, inhibition of IL-11 can promote the proliferation and regeneration of damaged cells (such as hepatocytes) and organ regeneration.
[0004] In practical applications, IL-11 is used in medicine by obtaining monoclonal antibodies, such as Boehringer Ingelheim developing monoclonal antibody drugs targeting IL-11 / IL-11Ra to develop first-in-class therapies for various fibroinflammatory diseases, and Lassen Therapeutics developing LASN01, a monoclonal antibody drug targeting IL-11Ra, which is expected to be a new treatment for fibrosis and tumor cancer, and will submit a new drug research application to the FDA in 2021 to start Phase I clinical trials. In the prior art, CN115975027A discloses an IL-11 humanized antibody and its application, which includes heavy chain variable region CDRs as shown in SEQ ID NOs: 4-6, light chain variable region CDRs as shown in SEQ ID NOs: 37-39, heavy chain framework regions as shown in SEQ ID NOs: 67-70, and light chain framework regions as shown in SEQ ID NOs: 71-74. This antibody has low immunogenicity and can specifically target and bind to IL-11, blocking the binding of IL-11 and IL-11 receptor. However, the affinity of the antigen obtained by humanizing the IL-11 antibody is relatively weak and still needs to be further improved.
[0005] Based on this, the present invention is proposed. Summary of the invention
[0006] To solve the above problems, the present invention provides an anti-IL-11 hybridoma antibody and its application in inhibiting fibrosis, the steps are as follows:
[0007] An anti-IL-11 hybridoma antibody comprises a heavy chain sequence and a light chain sequence, wherein the heavy chain sequence comprises 900910-VH1 and 900910-VH2, and the light chain sequence comprises 900910-VK1 and 900910-VK2.
[0008] The amino acid sequence of 900910-VH1 is
[0009] EVQLVESGGGLVQPGGSLRLSCAASGLTFSSFGMHWVRQAPGKGLEWVAYISGGS SITHYSDTVKGRFTISRDNAKNTLFLQMTSLRAEDTAVYYCALGFDYWGQGTTLTVSS;
[0010] The amino acid sequence of 900910-VH2 is
[0011] EVQLVESGGGLVQPGGSLRLSCAASGLTFSSFGMHWVRQAPGKGLEWVAYISGGS SITHYSDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCALGFDYWGQGTTLTVSS;
[0012] The amino acid sequence of 900910-VK1 is
[0013] DIVMTQSPSSSLSASVGDRVTITCKASQIVDTDVVWYQQKPGKAPKALIYSASYRYS GVPDRFTGSGSGTDFTLTISSLQPEDFATYFCQQYNSYPFTFGSGTKLEIK;
[0014] The amino acid sequence of 900910-VK2 is
[0015] DIVMTQSPSSSLSASVGDRVTITCKASQIVDTDVVWYQQKPGKAPKALIYSASYRYS GVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQYNSYPFTFGSGTKLEIK.
[0016] The method for preparing anti-IL-11 hybridoma antibodies is as follows:
[0017] Step 1: Use recombinant human IL11 / recombinant monkey IL11 protein as antigen, inject mice for cross-immunization, and finally obtain hybridoma cell lines that specifically bind to human, mouse, and monkey IL11;
[0018] Step 2: Obtaining the supernatant antibodies of the hybridoma cell line and performing affinity screening;
[0019] Step 3: Obtain variable region sequences based on TAKARA's 5'RACE technology;
[0020] Step 4: variable region gene amplification, transfection and expression to obtain anti-human IL-11 human-mouse chimeric antibody;
[0021] Step 5: Humanization design of anti-human IL-11 human-mouse chimeric antibody;
[0022] Based on TAKARA's 5'RACE technology, the heavy chain variable region gene and light chain variable region gene were obtained.
[0023] The anti-IL-11 chimeric antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCVR, VH-CDR1, VH-CDR2 and VH-CDR3, and the light chain variable region comprises HCVR, VL-CDR1, VL-CDR2 and VL-CDR3, and the amino acid sequence of the heavy chain variable region HCVR is DVQLVESGGGLVQPGGSRKLSCAASGLTFSSFGMHWVRQAPEKGLEWVAYISGGSSITHYSDTVKGRFTISRDNPKNTLFLQMTSLRSEDTAMYYCALGFDYWGQGTTLTVSS (SEQ ID NO: 1);
[0024] The amino acid sequence of the heavy chain variable region LCVR is DIVMTQSQKFMSTSVGDRVSVTCKASQIVDTDVVWYQKKPGHSPKALIYSASYRYSGV PDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNSYPFTFGSGTKLEIK (SEQ ID NO: 2);
[0025] Among them, the CDR sequence of the mouse anti-IL-11 antibody is as follows:
[0026]
[0027] The anti-IL-11 hybridoma antibody has good blocking activity for the formation of the IL-11 / IL-11Ra / GP130 ternary complex;
[0028] The humanization of antigen binding proteins adopts 3D modeling method, using PDB BLAST to retrieve the antibody crystal structure model with the closest sequence to determine the humanized framework region suitable for constructing the CDR-grafted heavy and light chains.
[0029] A total of 2 humanized heavy chain sequences 900910-VH1 and 900910-VH2, and 2 humanized light chain sequences 900910-VK1 and 900910-VK2 were designed.
[0030] 900910 heavy chain humanized sequence:
[0031] 900910-VH1:
[0032] EVQLVESGGGLVQPGGSLRLSCAASGLTFSSFGMHWVRQAPGKGLEWVAYISGGS SITHYSDTVKGRFTISRDNAKNTLFLQMTSLRAEDTAVYYCALGFDYWGQGTTLTVSS
[0033] 900910-VH2:
[0034] EVQLVESGGGLVQPGGSLRLSCAASGLTFSSFGMHWVRQAPGKGLEWVAYISGGS SITHYSDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCALGFDYWGQGTTLTVSS
[0035] 900910 light chain humanized sequence:
[0036] 900910-VK1:
[0037] DIVMTQSPSSSLSASVGDRVTITCKASQIVDTDVVWYQQKPGKAPKALIYSASYRYS GVPDRFTGSGSGTDFTLTISSLQPEDFATYFCQQYNSYPFTFGSGTKLEIK
[0038] 900910-VK2:
[0039] DIVMTQSPSSSLSASVGDRVTITCKASQIVDTDVVWYQQKPGKAPKALIYSASYRYS GVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQYNSYPFTFGSGTKLEIK.
[0040] Anti-IL-11 hybridoma antibodies can inhibit the production of fibrosis-related gene IL-11 induced by TGFβ.
[0041] Anti-IL-11 hybridoma antibodies can inhibit the expression of fibrosis-related protein FN induced by TGFβ.
[0042] Technical principle
[0043] Recombinant human IL11 / recombinant monkey IL11 protein was used as an antigen to prepare hybridoma cells that produce mouse monoclonal antibodies, obtain hybridoma cell lines that specifically bind to human, mouse and monkey IL11, and obtain hybridomas with good affinity for antibodies and antigens. The variable sequences of the obtained hybridoma 6G5 are 900910HCVR and 900910LCVR; based on the 5'RACE technology principle of TAKARA, the cDNA sequence of the mouse antibody variable region expressed by the hybridoma cell line was cloned to obtain The antibody variable region sequences were obtained, including the mouse anti-IL-11 antibody CDR sequences, heavy chain variable regions VH-CDR1, VH-CDR2, VH-CDR3 and light chain variable regions VL-CDR1, VL-CDR2, VL-CDR3, and the obtained vectors were amplified and expressed to obtain human-mouse chimeric antibodies. The anti-IL-11 human-mouse chimeric antibody 900910 had an affinity for both human and mouse IL-11 of the order of 10-09, and had extremely strong affinity for human, mouse and monkey antigens. At the same time, humanization adopted the homologous 3D modeling method, and finally obtained 2 humanized heavy chain sequences and 2 humanized light chain sequences, and obtained I600025 (VH1+VK1), I600026 (VH2+VK1), I600029 (VH1+VK2) and I600030 (VH2+VK2), a total of 4 900910 humanized antibodies. The affinity of the humanized molecules can reach the picomolar level.
[0044] In addition, the anti-IL-11 hybridoma antibody 900910 can inhibit the expression of fibrosis-related gene IL-11 and fibrosis-related protein FN induced by TGFβ. It has obvious effects in the anti-IL-11 antibody experiment in the UUO chronic renal fibrosis model, reducing the fibrosis area in fibrosis-related tissue staining. It can be used in clinical experiments and has broad medical prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] Figure 1 It is the activation of hIL11 Effector Report by anti-human IL-11 human-mouse chimeric antibody 900910;
[0046] Figure 2 The blocking activity of the anti-human IL-11 human-mouse chimeric antibody 900910 on the IL-11 / IL-11Ra / GP130 ternary complex;
[0047] Figure 3 The results of gene detection of IL-11 hybridoma antibody, where Data are expressed as means±SEM, n=3. *P≤0.05, as determined by one-way ANOVA;
[0048] Figure 4 This is an immunofluorescence detection picture;
[0049] Figure 5 Tissue staining pictures for UUO experiments;
[0050] Figure 6 Chronic fibrosis outcomes were analyzed for the UUO model. DETAILED DESCRIPTION
[0051] The present invention is further described below in conjunction with the accompanying drawings and specific examples. It should be understood that the specific embodiments described herein are only used to explain the present invention and do not limit the scope of protection of the present invention. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art. Unless otherwise specified, the raw materials and equipment used in this embodiment are conventional commercially available raw materials and equipment in the art.
[0052] Example
[0053] 1. Preparation of anti-IL-11 hybridoma antibodies
[0054] Step 1: Preparation of hybridoma cells producing mouse monoclonal antibodies
[0055] The method for preparing mouse monoclonal antibodies adopts the hybridoma preparation technology invented by Kohler and Milstein in 1975 (Nature, 1975, 256: 495-497). Recombinant human IL11 / recombinant monkey IL11 protein is used as an antigen, and Freund's adjuvant (Sigma, Cat No: F5881 / F5506) is used for full emulsification and immunization. Balb / C, CD1 and other strains of mice are immunized by multiple subcutaneous injections, and recombinant human IL11 / recombinant monkey IL11 proteins are cross-immunized respectively. After three immunizations, blood is collected and the mouse serum titer is measured by ELISA. When the serum titer reaches the target value, a pre-fusion surprise immunization is performed. The mouse with the highest titer is selected to obtain spleen cells and fuse with SP2 / 0 myeloma cells. Hybridoma cell lines were screened using HAT-containing culture medium, and the hybridoma cell supernatant was screened by ELISA to select hybridoma clones that bind to human IL11; the hybridoma supernatant was then tested by ELISA for specific binding to monkey and mouse IL11 to obtain hybridoma cell lines that specifically bind to human, mouse, and monkey IL11. The supernatant antibody affinity of the screened hybridoma cells was tested. Finally, the hybridoma cell line expressing the Hu-IL11 antibody was sequenced.
[0056] Step 2: Antibody affinity screening of hybridoma cell culture supernatant
[0057] Step 2: Use the SPR method to determine the affinity between the antibody and antigen in the hybridoma supernatant. The required test materials and instruments are as follows:
[0058]
[0059]
[0060] Experimental method used in step 2:
[0061] The sample chamber and flow cell temperature of Biacore 8K were set to 25°C, and the data collection frequency was 10 Hz. Anti-mouse antibodies were amino-coupled to the CM5 chip according to the instructions for the mouse antibody capture kit (Cytiva, Cat#BR100838). The CM5 chip coupled with anti-mouse antibodies was used to capture the antibodies in the culture supernatant as ligands. Human, monkey and mouse IL-11 antigens were diluted to 50 nM with running buffer (1 mg / mL CM-Dextran sodium salt, 1 mg / mL Bovine Serum Albumin, HBS-EP+, pH7.4 buffer) as analytes, and the running buffer was used as the zero concentration for background subtraction. The Kinetic screening method was used, with the analyte flow rate set to 30 μL / min, the binding time to 120 s, the dissociation time to 180 s, and the regeneration of 10 mM glycine (pH1.5) at 50 μL / min for 60 s. The data were analyzed in 1:1 binding mode and Fit Local Kinetics mode. The results are shown in Table 1.
[0062] Table 1: Hybridoma affinity screening data
[0063]
[0064]
[0065] Step 3: Cloning of variable region gene of anti-human IL-11 antibody
[0066] Based on the principle of TAKARA's 5'RACE technology, the cDNA sequence of the variable region of the mouse antibody expressed by the hybridoma cell line was cloned. In short, the variable region gene-specific cDNA of the heavy chain and light chain was synthesized according to the instructions using the SMARTer 5'RACE synthesis kit (TAKARA, Cat. No. 634859). The 5' and 3' ends of the cDNA sequence were modified with PCR primers, and the primers were designed to add appropriate leading sequences to the heavy chain and light chain variable region cDNAs, respectively, so that the resulting PCR products could be cloned into the existing recombinant antibody expression heavy chain vector pHB-Fc and light chain vector pHB-Cκ by seamless cloning. The pHB-Fc expression vector contains the human IgG1 heavy chain constant region gene sequence, in which CH2 carries L234A and L235A (Eunumbering) mutations that weaken the antibody ADCC effect; the pHB-Cκ vector contains the human κ light chain constant region gene sequence. The heavy chain and light chain variable region PCR amplification products were cloned into the expression vector by In-fusion cloning reagent (TAKARA, item number 639650) to obtain the human-mouse chimeric antibody expression vector, and transformed into Stellar TM Competent Cells Escherichia coli competent cells (TAKARA, item number 636763). The antibody variable region sequence was obtained by selecting monoclonal colonies for Sanger sequencing and analyzing. As a result, an anti-IL-11 chimeric antibody (Huabo number 900910) was obtained, which was derived from the hybridoma 6G5 in Example 1, and its variable region sequence is as follows:
[0067] 900910HCVR SEQ ID NO: 1
[0068] DVQLVESGGGLVQPGGSRKLSCAASGLTFSSFGMHWVRQAPEKGLEWVAYISGGS SITHYSDTVKGRFTISRDNPKNTLFLQMTSLRSEDTAMYYCALGFDYWGQGTTLTVSS
[0069] 900910LCVR SEQ ID NO: 2
[0070] DIVMTQSQKFMSTSVGDRVSVTCKASQIVDTDVVWYQKKPGHSPKALIYSASYRY SGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNSYPFTFGSGTKLEIK
[0071] The underlined area is CDRs (IMGT definition, listed separately below)
[0072] Table 2 CDR sequences of mouse anti-IL-11 antibodies
[0073]
[0074] Step 4: Expression of anti-human IL-11 human-mouse chimeric antibody
[0075] The expression vector obtained in step 3 was amplified by Escherichia coli, and a sufficient amount of plasmid was prepared using an endotoxin-free plasmid extraction kit (Tiangen Biochemical Technology (Beijing) Co., Ltd., Catalog No. DP117) for transient transfection and expression of chimeric antibodies. The host cells used for expression were CHO-S cells (Thermo Fisher, Catalog No. R80007). The two heavy chain vectors prepared were mixed with the light chain vectors, respectively, and polyetherimide (PEI, Polysciences, Catalog No. 24765-1) to form a liposome complex, and then transfected into CHO-S cells and cultured in a carbon dioxide shaker for 7 days. The cell culture supernatant was collected by centrifugation and purified by Protein A affinity chromatography to obtain human-mouse chimeric antibodies.
[0076] A human-mouse chimeric antibody affinity test for human and mouse IL-11
[0077] Purpose of the experiment: This experiment uses the SPR method to determine the kinetic constants of human and mouse IL-11 binding to antibodies.
[0078] Test materials and instruments:
[0079]
[0080]
[0081] Experimental methods:
[0082] The sample chamber and flow cell temperature of Biacore 8K were set to 25°C, and the data collection frequency was 10 Hz. Series SProtein A chips captured antibody samples to 300 RU as ligands. Human and mouse IL-11 antigens were diluted with HBS-EP+, pH7.4 buffer to a series of gradient concentrations of 50 nM, 25 nM, 12.5 nM, 6.25 nM, 3.125 nM, 1.56 nM, 0.78 nM and 0.39 nM as analytes, and HBS-EP+, pH7.4 buffer was used as the 0 concentration for background subtraction. A multi-cycle kinetic method was used, with an analyte flow rate of 30 μL / min, a binding time of 120 s, a dissociation time of 600 s, and a regeneration of 10 mM glycine (pH1.5) at 50 μL / min for 60 s. Data were analyzed in 1:1 binding mode and Fit Local Kinetics mode.
[0083] Experimental results:
[0084] Table 3. Affinity test results of anti-human IL-11 human-mouse chimeric antibody 900910 and human and mouse IL-11
[0085] Sample Antigen ka(1 / Ms) kd(1 / s) KD(M) 900910 Human IL-11 3.18E+05 1.85E-03 5.82E-09 900910 Mouse IL-11 3.13E+05 1.97E-03 6.31E-09
[0086] The results of affinity constants (KD(M)) with various species showed that the affinity of the anti-IL-11 human-mouse chimeric antibody 900910 of the present invention with human and mouse IL-11 was on the order of 10-09, and it had extremely strong affinity for human and mouse antigens.
[0087] B. Affinity test of humanized monoclonal antibody and monkey IL-11
[0088] Purpose of the experiment: This experiment uses the SPR method to determine the monkey antigen-antibody binding kinetic constants.
[0089] Test materials and instruments:
[0090]
[0091]
[0092] Experimental methods:
[0093] The sample chamber and flow cell temperature of Biacore 8k were set to 25°C, and the data collection frequency was 10 Hz. Cynomolgus IL-11 was amino-coupled and immobilized on the Series S Sensor Chip CM5 chip using the Amine Coupling Kit as a ligand. The sample was diluted with HBS-EP+, pH7.4 buffer into a series of gradient concentrations as the analyte, and HBS-EP+, pH7.4 buffer was used as the 0 concentration for background subtraction. A single-cycle kinetic method was used, with an analyte flow rate of 30 μL / min, a binding time of 120 s, a dissociation time of 600 s, and a regeneration of 10 mM glycine (pH1.5) at 50 μL / min for 60 s. Data were analyzed in 1:1 binding mode and FitLocal Kinetics mode.
[0094] The experimental results are shown in the following table.
[0095] Table 4. Affinity test results of anti-human IL-11 human-mouse chimeric antibody 900910 and monkey IL-11
[0096] Sample Antigen ka(1 / Ms) kd(1 / s) KD(M) 900910 Cynomolgus IL-11 3.21E+05 1.72E-03 5.37E-09
[0097] The affinity constant (KD(M)) results show that the affinity of the anti-IL-11 human-mouse chimeric antibody 900910 of the present invention to monkey IL-11 is on the order of 10-09, and has a very strong affinity for monkey antigens.
[0098] C Anti-IL-11 antibody blocks IL-11-mediated activation of hIL11 Effector Reporter Cells
[0099] hIL11 Effector Report (Nanjing Kebai, cat#CBP74114) with good growth status were collected and counted, resuspended in culture medium (ingredients: DMEM+10% FBS) to a cell suspension of 1.2E6 cells / mL, and plated into a 96-well white plate (Jingan Bio, cat#J09601) at 50 μL / well; antibody I600030 was diluted to 200 nM with culture medium, and continued to be diluted 3-fold to 10 concentrations, with a total of 11 concentration gradients; the diluted antibody was added to the 96-well white plate at 25 μL / well; IL11 protein (Jinan, cat#C006) was diluted to 0.2 ng / mL, and added to the 96-well white plate at 25 μL / well; the side wells were sealed with PBS liquid at 100 μL / well, and cultured for 6 hours at 37°C and 5% CO2; at the end of incubation, the plate was taken out and balanced for 15 minutes, and 100 μL / well was added UltraLuciferase Detection Kit (YaKeYuan, cat#A2000301N) was used for 5 minutes of reaction and full wavelength detection was performed by microplate reader. GraphPad Prism 8 software was used to fit the data with a four-parameter equation based on the sample working concentration-bioluminescence reading to obtain the sample dose-effect curve.
[0100] Table 5. Anti-human IL-11 human-mouse chimeric antibody 900910 and biological activity test results
[0101] Sample R2 Bioactivity(nM) 900910 0.9862 0.085
[0102] D Analysis of the blocking activity of anti-IL-11 antibodies in blocking the formation of IL-11 / IL-11Ra / GP130 ternary complex
[0103] In this experiment, the competitive ELISA method was used to analyze the blocking activity of anti-IL-11 antibodies on the formation of the IL-11 / IL-11Ra / GP130 ternary complex. Human IL-11Ra (Sino Biological Inc. Cat#: 10252-H08H) was added to the ELISA plate and coated overnight; the samples were prepared on the next day, first 0.4 μg / mL of human IL-11 (Sino Biological Inc. Cat#: 12225-HNCE) was prepared, and then it was mixed with equal volumes of gradiently diluted anti-IL-11 antibody (dilution concentration: 300, 100, 33.33, 11, 11, 3.70, 1.23, 0.41, 0.14, 0.046, 0.015, 0.0051 μg / mL) in a 1:1 ratio, and then added to the ELISA plate coated with IL-11Ra for incubation, and finally 2 μg / mL of GP130 (Sino Biological Inc. Cat#: 10974-H05H) was added for co-incubation. After one hour, the cells were washed and HRP-labeled anti-mouse Fc secondary antibody was added for color development and OD450 was used to detect the absorbance. The final experimental results showed that 900910 had good blocking activity for the formation of IL-11 / IL-11Ra / GP130 ternary complex, with an IC50 of 3.3 nM.
[0104] Step 5 Humanization design of anti-IL-11 mouse chimeric antibody 900910
[0105] The humanization of antigen binding proteins uses the 3D modeling method: first, the mouse antigen binding protein is modeled in three dimensions, the optimal structural model is selected, and 5-10 optimal structural solutions are selected using the homology modeling method. The loop region is generally modeled using the homology modeling method. If the CDR amino acid sequence alignment result shows less than 50% Identity, the CDR3 structural model is built using the de novo modeling method. Use PDB BLAST to retrieve the 10 antibody crystal structure models with the closest sequence (structural resolution is higher than 2.5 angstroms), compare the automatic modeling model, and select the optimal structural model. Then compare the variable region sequence of the antigen binding protein with the available sequences in the NCBI IgBlast database. Through identification and analysis, the human framework region (FR region) suitable for constructing CDR transplanted heavy and light chains is finally determined.
[0106] During the modification, the modification sites were designed based on the conserved amino acid residues in the FR region of human antibodies and the important amino acid residues in the FR region of antibodies, and the variable regions of the heavy and light chains of the antigen-binding protein 900910 of the present application were respectively designed for humanized mutations. The designed humanized sequences should meet the requirements of not affecting the structural stability of the antibody, not affecting the binding of the antigen-binding protein to the antigen, not introducing protein modification sites such as glycosylation and phosphorylation, not introducing sites that are easily oxidized and aminated, and enhancing structural stability. After analysis, a total of 2 humanized heavy chain sequences and 2 humanized light chain sequences were designed for the mouse antigen-binding protein sequence of 900910, and the sequences are shown in the following table:
[0107] 900910 heavy chain humanized sequence:
[0108] 900910-VH1:
[0109] EVQLVESGGGLVQPGGSLRLSCAASGLTFSSFGMHWVRQAPGKGLEWVAYISGGS SITHYSDTVKGRFTISRDNAKNTLFLQMTSLRAEDTAVYYCALGFDYWGQGTTLTVSS
[0110] 900910-VH2:
[0111] EVQLVESGGGLVQPGGSLRLSCAASGLTFSSFGMHWVRQAPGKGLEWVAYISGGS SITHYSDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCALGFDYWGQGTTLTVSS
[0112] 900792 light chain humanized sequence:
[0113] 900910-VK1:
[0114] DIVMTQSPSSSLSASVGDRVTITCKASQIVDTDVVWYQQKPGKAPKALIYSASYRYS GVPDRFTGSGSGTDFTLTISSLQPEDFATYFCQQYNSYPFTFGSGTKLEIK
[0115] 900910-VK2:
[0116] DIVMTQSPSSSLSASVGDRVTITCKASQIVDTDVVWYQQKPGKAPKALIYSASYRYS GVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQYNSYPFTFGSGTKLEIK
[0117] Note: The italic underlined sequences are antibody CDR sequences, and the CDR sequence division method is based on the KabaT format.
[0118] The above two 900910 heavy chain humanized sequences and two 900910 light chain humanized sequences were randomly combined to obtain four 900910 humanized antibodies, I600025 (VH1 + VK1), I600026 (VH2 + VK1), I600029 (VH1 + VK2) and I600030 (VH2 + VK2), which were expressed and purified by CHO-S cells. The binding ability of 900910 humanized proteins to IL-11 antigen and the activity of blocking IL-11 and its receptor binding were screened by flow cytometry, Biacore and other detection methods, and multiple humanized anti-IL-11 antigen binding proteins with excellent performance were obtained, among which I600030 was analyzed as the best molecule among the humanized molecules.
[0119] Table 6. Humanized sequence of anti-human IL-11 human-mouse chimeric antibody 900910
[0120]
[0121]
[0122]
[0123]
[0124]
[0125]
[0126]
[0127] Table 7. Anti-human IL-11 human-mouse chimeric antibody 900910 humanized molecule affinity and blocking activity test results
[0128]
[0129] II. In vitro inhibition of fibrosis by IL-11 hybridoma antibodies
[0130] The anti-IL-11 hybridoma antibody 900910 was tested for its ability to inhibit TGFβ (transforming growth factor β)-induced fibrosis in NICH0018 (healthy human skin fibroblasts).
[0131] qPCR detection:
[0132] After removing the culture medium (89% DMEM (Double-Biotinylated Medium) + 10% FBS (fetal bovine serum) + 1% P / S (penicillin, streptomycin)) from the NICH0018 cells in the logarithmic growth phase in the culture flask, wash twice with 10mL PBS, add 2mL 0.25% trypsin, and digest in an incubator (37°C, 5% carbon dioxide) for 3-5 minutes. After adding culture medium to terminate digestion, obtain cell suspension, centrifuge (500g×5min), discard the culture medium, resuspend in culture medium to 1mL, and count on a counter. Plate 5×105 cells per well in a six-well plate, replenish culture medium to 2mL per well, culture in an incubator for 8h to adhere, replace with complete culture medium (DMEM without FBS) and starve for 16h. The culture medium was prepared according to the final concentration of 10ng / ml TGFβ or 15μg / ml 900910. After the original culture medium was removed, 2mL of ordinary culture medium was added to the blank group, 2mL of 10ng / ml TGF-beta culture medium was added to the stimulation group, and 2mL of culture medium with a final concentration of 10ng / ml TGF-beta and 15μg / ml 900910 was added to the antibody group, with three replicates in each group. After incubation in the incubator for 24h, the cells were washed twice with PBS, and the cells were collected into EP tubes without RNAse using a cell scraper, and the cell pellets were obtained by centrifugation (500g×5min).
[0133] RT-PCR was used to detect the expression of fibrosis-related genes IL-11 (encoding IL-11 protein) and COLIV (encoding type IV collagen) in cells. Add 350ul Buffer RLT to the cell pellet and mix it with the cells to lyse evenly. Add 350ul of 70% ethanol to the lysate and mix evenly. Transfer the previous lysate to a 2ml collection tube containing an RNeasy MinElute spin column, centrifuge at 8000g for 15s, and discard the filtrate. Add 350ul Buffer RW1 to the RNeasy MinElute spin column, centrifuge at 8000g for 15s, and discard the filtrate. Place the RNeasy MinElute spin column in a new 2ml collection tube, add 500ul Buffer RPE, centrifuge at 8000g for 15s, and discard the filtrate. Add 500ul 80% ethanol to the RNeasy MinElute spincolumn, centrifuge at 8000g for 2min, and discard the collection tube. Place the RNeasy MinElute spincolumn in a new 2ml collection tube, centrifuge at the highest speed of the centrifuge for 5 minutes with the lid open, and discard the filtrate and collection tube. Place the RNeasy MinElute spin column in a new 1.5ml collection tube, drop 14ul RNase-free water in the center of the adsorption column, centrifuge at the highest speed of the centrifuge for 1 minute, elute the RNA and then detect the RNA concentration. The genome removal reaction system and reaction conditions are as follows:
[0134] Table 8. Reaction system components
[0135] Reagent name Volume (μL) 5X gDNA Eraser Buffer 2ul gDNA Eraser 1ul Total RNA 250ng <![CDATA[RNase Free dH2O]]> Up to 10ul
[0136] Table 9. Reaction time of reaction system
[0137] Temperature(℃) time 42 2min 4 ∞
[0138] After obtaining the reaction solution with the reaction group removed, a reverse transcription reaction is performed. The reaction system and reaction conditions are as follows:
[0139] Table 10. Reaction system components
[0140]
[0141] Table 11 Relationship between reaction temperature and reaction time
[0142]
[0143]
[0144] Tables 8 to 11 reflect the relationship between different reaction systems and reaction times. It can be seen that the reaction temperature of the system should be maintained at 37-42°C.
[0145] After obtaining cDNA, perform quantitative PCR:
[0146] Prepare the reaction solution according to the table below and add the mixed solution to the corresponding reaction tubes, 5.6 μL each. Mix 1 μL cDNA sample with 3.4 μL DEPC H2O and add to the corresponding wells. Set up a negative control well at the same time, and the template is sterile water.
[0147] Table 12. Reaction solution system components
[0148] Reagents volume 2×Fast SYBE Green Master Mix 5μL Forward Primer (10μM) 0.3μL Reverse Primer (10μM) 0.3μL
[0149] Program setting: Use the comparative CT (ΔΔCT) method and set the software to run the program. PCR amplification program: denaturation at 95 degrees for 10 minutes, 1 cycle; denaturation at 95 degrees for 15 seconds, extension at 60 degrees for 30 seconds, 40 cycles; denaturation at 95 degrees for 15 seconds, extension at 60 degrees for 1 minute, 0.15 degree gradient rise to 95 degrees. Run quantitative PCR.
[0150] Genetic testing results are available at Figure 3 The results showed that the anti-IL-11 hybridoma antibody 900910 could inhibit the increase of fibrosis-related genes IL-11 and COLIV induced by TGFβ. It proved that 900910 could inhibit the fibrosis of NICH0018 cells induced by TGFβ.
[0151] Immunofluorescence detection:
[0152] After removing the culture medium (89% DMEM (Dunbury medium) + 10% FBS (fetal bovine serum) + 1% P / S (penicillin, streptomycin)) from the NICH0018 cells in the logarithmic growth phase in the culture flask, wash twice with 10mL PBS, add 2mL 0.25% trypsin, and digest in an incubator (37°C, 5% carbon dioxide) for 3-5 minutes. After adding culture medium to terminate digestion, obtain cell suspension, centrifuge (500g×5min), discard the culture medium, resuspend to 1mL with culture medium, and count on a counter. 1×10 cells per well 5The number of cells was plated into a twelve-well plate with a treated cover glass placed in advance, and the culture medium was supplemented to 2 mL per well. After culturing in the incubator for 8 hours to adhere to the wall, the complete culture medium (DMEM without FBS) was replaced for starvation treatment for 16 hours. The culture medium was prepared according to the final concentration of 10 ng / ml TGFβ or 15μg / ml 900910. After aspirating the original culture medium, 2 mL of ordinary culture medium was added to the blank group, 2 mL of 10 ng / ml TGF-beta culture medium was added to the stimulation group, and 2 mL of culture medium with a final concentration of 10 ng / ml TGF-beta and 15μg / ml 900910 was added to the antibody group. Each group was repeated three times. After incubation in the incubator for 24 hours, the culture plate was removed, the culture medium was discarded, and PBS was washed three times. The slides were fixed with 4% paraformaldehyde at room temperature for 15 minutes, and the slides were washed with PBS three times. Incubate the slides at room temperature for 10 min with Beyotime immunostaining blocking solution, wash the slides 3 times with PBS, dilute Fibronectin-AF488 (1:200) and TRITC-phalloidin (1:1000) with Beyotime immunostaining primary antibody diluent, and incubate overnight at 4°C. Wash the slides 3 times with Beyotime immunostaining washing solution, 3 min each time. Add a drop of Thermo Fisher ProLong TM Glass antifade mounting medium (containing NucBlue TM Dye), take out the treated cell slides, and seal the slides with the cells facing down. Use Olympus CKX53 fluorescence inverted microscope to collect 420nm fluorescence signal (nucleus) excited by 340-390nm fluorescence, 510nm fluorescence signal (fibronectin) excited by 460-495nm fluorescence, and 575nm fluorescence signal (phalloidin) excited by 530-550nm fluorescence, and use ImageJ software to merge the images of each channel.
[0153] The results of immunofluorescence staining were shown in Figure 2 The results showed that the anti-IL-11 hybridoma antibody 900910 could inhibit the expression of fibrosis-related protein FN induced by TGFβ. It proved that 900910 could inhibit the fibrosis of NICH0018 cells induced by TGFβ.
[0154] Pharmacodynamic evaluation of anti-IL-11 antibody in a chronic renal injury model induced by unilateral ureteral ligation (UUO)
[0155] The pharmacodynamics of anti-IL-11 antibodies were evaluated in the UUO chronic renal fibrosis model. Mice were randomly divided into 4 groups, with 6 mice in each group. There were 6 normal control groups, 6 IgG control groups (administered control IgG antibodies, 30 mg / kg), 6 positive control groups (valsartan, 30 mg / kg), and 6 900910 groups (30 mg / kg). On the day of surgery, inhalation anesthesia was used to ligate the left ureter of the mice. One day after the UUO surgery, medication was started, and the medication was given twice a week for a total of 3 weeks (a total of 6 times). The weight of the animals was weighed before sampling. Blood was collected, serum was packaged, and stored at -80°C. The kidneys on the surgical side were taken and weighed; some were stored in formalin (for tissue staining). The detection indicators included: serum creatinine content, serum urea nitrogen content, renal tissue PAS staining, Masson-trichrome and FN staining. GraphPad Prism8.0 was used for data analysis.
[0156] The analysis results showed that the normal control group had no obvious renal fibrosis and renal function impairment. However, in the modeling group (IgG control group), obvious tissue fibrosis occurred. The administration of control drugs and anti-IL-11 antibody drugs showed different degrees of inhibitory effects on fibrosis, which was reflected in the reduction of fibrosis area in fibrosis-related tissue staining.
Claims
1. An anti-IL-11 hybridoma antibody, characterized in that The anti-IL-11 hybridoma antibody comprises a heavy chain sequence and a light chain sequence, wherein the heavy chain sequence comprises 900910-VH1 and 900910-VH2, and the light chain sequence comprises 900910-VK1 and 900910-VK2. The amino acid sequence of 900910-VH1 is EVQLVESGGGLVQPGGSLRLSCAASGLTFSSFGMHWVRQAPGKGLEWVAYISGGS SITHYSDTVKGRFTISRDNAKNTLFLQMTSLRAEDTAVYYCALGFDYWGQGTTLTVSS; The amino acid sequence of 900910-VH2 is EVQLVESGGGLVQPGGSLRLSCAASGLTFSSFGMHWVRQAPGKGLEWVAYISGGS SITHYSDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCALGFDYWGQGTTLTVSS; The amino acid sequence of 900910-VK1 is DIVMTQSPSSLSASVGDRVTITCKASQIVDTDVVWYQQKPGKAPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISSLQPEDFATYFCQQYNSYPFTFGSGTKLEIK; The amino acid sequence of 900910-VK2 is DIVMTQSPSSLSASVGDRVTITCKASQIVDTDVVWYQQKPGKAPKALIYSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQYNSYPFTFGSGTKLEIK.
2. The anti-IL-11 hybridoma antibody according to claim 1, characterized in that: The preparation method of the anti-IL-11 hybridoma antibody is: Step 1: Use recombinant human IL11 / recombinant monkey IL11 protein as antigen, inject mice for cross-immunization, and finally obtain hybridoma cell lines that specifically bind to human, mouse, and monkey IL11; Step 2: Obtaining the supernatant antibodies of the hybridoma cell line and performing affinity screening; Step 3: Obtain variable region sequences based on TAKARA's 5'RACE technology; Step 4: variable region gene amplification, transfection and expression to obtain anti-human IL-11 human-mouse chimeric antibody; Step 5: Humanization design of anti-human IL-11 human-mouse chimeric antibody.
3. The anti-IL-11 hybridoma antibody according to claim 2, characterized in that: In step 3, based on TAKARA's 5'RACE technology, the heavy chain variable region gene and the light chain variable region gene are obtained; In step 4, the anti-IL-11 chimeric antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCVR, VH-CDR1, VH-CDR2, and VH-CDR3, and the light chain variable region comprises HCVR, VL-CDR1, VL-CDR2, and VL-CDR3, and the amino acid sequence of the heavy chain variable region HCVR is DVQLVESGGGLVQPGGSRKLSCAASGLTFSSFGMHWVRQAPEKGLEWVAYISGGSSITHYSDTVKGRFTISRDNPKNTLFLQMTSLRSEDTAMYYCALGFDYWGQGTTLTVSS (SEQ ID NO: 1); The amino acid sequence of the heavy chain variable region LCVR is DIVMTQSQKFMSTSVGDRVSVTCKASQIVDTDVVWYQKKPGHSPKALIYSASYRYSGV PDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNSYPFTFGSGTKLEIK (SEQ ID NO: 2); Among them, the CDR sequence of the mouse anti-IL-11 antibody is as follows:
4. The anti-IL-11 hybridoma antibody according to claim 2, characterized in that: The humanization of antigen binding proteins adopts 3D modeling method, using PDB BLAST to retrieve the antibody crystal structure model with the closest sequence to determine the humanized framework region suitable for constructing the CDR-grafted heavy and light chains.
5. The anti-IL-11 hybridoma antibody according to claim 1, characterized in that: The anti-IL-11 hybridoma antibody has good blocking activity for the formation of IL-11 / IL-11Ra / GP130 ternary complex.
6. The anti-IL-11 hybridoma antibody according to claim 1, characterized in that: The anti-IL-11 hybridoma antibody can inhibit the fibrosis-related gene IL-11 induced by TGFβ.
7. The anti-IL-11 hybridoma antibody according to claim 1, characterized in that: The anti-IL-11 hybridoma antibody can inhibit the expression of fibrosis-related protein FN induced by TGFβ.
Citation Information
Patent Citations
Group of IL-11 monoclonal antibodies and medical application thereof
CN113980129A
Anti-IL-11 cytokine humanized antibodies
CN118307670A
